Madison Ponder

Madison Ponder

Auto-generated profile, based on publicly available information

Madison Ponder

Department of Epidemiology Gillings School of Global Public Health, University of North Carolina Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in JMIR Perioperative Medicine
Verified
Journal Article
Open access
MPMadison Ponder
Madison Ponder
AAAbena A. Ansah-Yeboah
Abena A. Ansah-Yeboah
LCLefko T. Charalambous
Lefko T. Charalambous
SASyed M. Adil
Syed M. Adil
VVVishal Venkatraman
Vishal Venkatraman
SLShivanand P. Lad
Shivanand P. Lad
Background: There is a great unmet clinical need to provide patients undergoing spinal surgery and their caregivers with ongoing, high-quality care before and after surgery in an efficiency-focused health care environment. Objective: The objective of this study is to design, develop, and evaluate the acceptability and feasibility of a novel planning-, outcomes-, and analytics-based smartphone app called ManageMySurgery (MMS) in patients undergoing elective spine surgery (MMS-Spine). Methods: The development process of the MMS app was conducted over 2 sequential stages: (1) an evidence-based intervention design with refinement from surgeon and patient feedback and (2) feasibility testing in a clinical pilot study. We developed a novel, mobile-based, Health Insurance Portability and Accountability Act–compliant platform for interventional and surgical procedures. It is a patient-centric mobile health app that streamlines patients’ interactions with their care team. MMS divides the patient journey into phases, making it feasible to provide customized care pathways that meet patients’ unique needs. Patient-reported outcomes are easily collected and conform to the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) standard. Results: We tested the feasibility of the MMS-Spine app with patients undergoing elective spine surgery at a large academic health system. A total of 47 patients undergoing elective spine surgery (26 cervical spine and 21 lumbar spine surgeries) downloaded and used MMS-Spine to navigate their surgical journey, quantify their baseline characteristics and postoperative outcomes, and provide feedback on the utility of the app in preparing for and recovering from their spinal surgery. The median age was 59.0 (range 33-77) years, 22 of the 47 patients (47%) were women, and 26 patients (55%) had commercial insurance. Of the 47 patients, a total of 33 (70%) logged in on an iOS device, 11 (23%) on an Android device, and 3 (6%) on a computer or tablet. A total of 17 of the 47 patients (36%) added a caregiver, of which 7 (41%) logged in. The median number of sign-ins was 2. A total of 38 of 47 patients (81%) completed their baseline preoperative PROMIS-29 outcomes, and 14 patients (30%) completed at least one PROMIS-29 survey during the postoperative period. Of the 24 patients who completed the MMS survey, 21 (88%) said it was helpful during preparation for their procedure, 16 (67%) said it was helpful during the postoperative period, and 23 (96%) said that they would recommend MMS to a friend or family member. Conclusions: We used a patient-centered approach based on proven behavior change techniques to develop a comprehensive smartphone app for patients undergoing elective spine surgery. The optimized version of the app is ready for formal testing in a larger randomized clinical study to establish its cost-effectiveness and effect on patients’ self-management skills and long-term outcomes.

1 September 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
MPMadison Ponder
Madison Ponder
VVVishal Venkatraman
Vishal Venkatraman
LCLefko Charalambous
Lefko Charalambous
AAAbena A. Ansah-Yeboah
Abena A. Ansah-Yeboah
SASyed M. Adil
Syed M. Adil
JPJennifer K. Plichta
Jennifer K. Plichta
PURPOSE: Contemporary breast cancer surgery often requires hospital stays of 1 day or less, presenting challenges to delivery of high-quality care. Without sufficient time for proper education and guidance, patients may delay seeking care, experience anxiety, or seek unnecessary care, leading to poorer outcomes and increased costs. To address this, we evaluated the feasibility of a planning-, outcomes-, and analytics-based mobile health application called Manage My Surgery (MMS) for patients undergoing elective breast cancer surgery. METHODS: Patients undergoing breast cancer surgery at an academic health center were invited to use MMS. Those who used the application received pre- and postoperative surveys, which recorded and reported patient satisfaction and outcomes related to the application. RESULTS: Thirty-three female patients undergoing elective breast cancer surgery used MMS. The median age was 58 years. Nineteen patients underwent lumpectomy, and 14 underwent mastectomy. Users logged on to the application an average of 3.5 times. The median number of questions viewed was 12 (range 2-35). Of 17 patients who completed the feedback survey, 100% said that MMS was helpful during preparation for surgery, 82.3% said that MMS was helpful postoperatively, and 94.1% would recommend MMS to others. Preliminary data on patient-reported outcomes collected by MMS suggest improvements in anxiety and depression over time. CONCLUSION: Implementation of a digital care navigation tool in breast cancer surgery patients is feasible. Patients found the tool helpful in both the pre- and postoperative period. Additional ongoing work will focus on patients' self-management skills, long-term outcomes, and health system costs.

26 October 2022 in JMIR Perioperative Medicine
Verified
Journal Article
Open access
VVVishal Venkatraman
Vishal Venkatraman
EKElayna Kirsch
Elayna Kirsch
ELEmily Luo
Emily Luo
SKSameer Kunte
Sameer Kunte
MPMadison Ponder
Madison Ponder
SLShivanand P. Lad
Shivanand P. Lad
Background: Digital health solutions have been shown to enhance outcomes for individuals with chronic medical illnesses, but few have been validated for surgical patients. The digital health platform ManageMySurgery (MMS) has been validated for spine surgery as a feasible method for patients along their surgical journey through in-app education and completion of patient-reported outcomes surveys. Objective: The aim of this study is to determine the rates of 90-day emergency room (ER) visits, readmissions, and complications in patients undergoing spine surgery using MMS compared to patients using traditional perioperative care alone. Methods: Patients undergoing spine surgery at a US-based academic hospital were invited to use MMS perioperatively between December 2017 and September 2021. All patients received standard perioperative care and were classified as MMS users if they logged into the app. Demographic information and 90-day outcomes were acquired via electronic health record review. The odds ratios of having 90-day ER visits, readmissions, mild complications, and severe complications between the MMS and non-MMS groups were estimated using logistic regression models. Results: A total of 1015 patients were invited, with 679 using MMS. MMS users and nonusers had similar demographics: the average ages were 57.9 (SD 12.5) years and 61.5 (SD 12.7) years, 54.1% (367/679) and 47.3% (159/336) were male, and 90.1% (612/679) and 88.7% (298/336) had commercial or Medicare insurance, respectively. Cervical fusions (559/1015, 55.07%) and single-approach lumbar fusions (231/1015, 22.76%) were the most common procedures for all patients. MMS users had a lower 90-day readmission rate (55/679, 8.1%) than did nonusers (30/336, 8.9%). Mild complications (MMS: 56/679, 8.3%; non-MMS: 32/336, 9.5%) and severe complications (MMS: 66/679, 9.7%; non-MMS: 43/336, 12.8%) were also lower in MMS users. MMS users had a lower 90-day ER visit rate (MMS: 62/679, 9.1%; non-MMS: 45/336, 13.4%). After adjustments were made for age and sex, the odds of having 90-day ER visits for MMS users were 32% lower than those for nonusers, but this difference was not statistically significant (odds ratio 0.68, 95% CI 0.45-1.02; P=.06). Conclusions: This is one of the first studies to show differences in acute outcomes for people undergoing spine surgery who use a digital health app. This study found a correlation between MMS use and fewer postsurgical ER visits in a large group of spine surgery patients. A planned randomized controlled trial will provide additional evidence of whether this digital health tool can be used as an intervention to improve patient outcomes.

17 April 2022 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
VVVishal Venkatraman
Vishal Venkatraman
MPMadison Ponder
Madison Ponder
ZGZiad F. Gellad
Ziad F. Gellad
SLShivanand P. Lad
Shivanand P. Lad
ECEdana Christy
Edana Christy
JDJulie Doberne
Julie Doberne

22 June 2020 in Public Library Quarterly
Verified
Journal Article
Closed access
JWJordan Wrigley
Jordan Wrigley
CKCaitlin Kennedy
Caitlin Kennedy
MFMary Grace Flaherty
Mary Grace Flaherty
MPMadison Ponder
Madison Ponder
MFMeg Foster
Meg Foster
JAJesse Akman
Jesse Akman
This study sought to investigate the opioid epidemic impact on North Carolina public libraries. Libraries in half of all 100 counties were chosen through a random, geographically systematic process, and structured interviews were completed with library directors. Twenty directors were interviewed, representing 28 counties. All reported their communities were affected; nine reported direct impacts on library function. Fifteen directors felt libraries should be involved in response; some felt Narcan administration was beyond library purview. Two libraries reported having Narcan available; five reported providing staff training. Given librarians’ willingness to respond, it is time to provide necessary support for those efforts.

7 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CLChase Doyne Latour
Chase Doyne Latour
MPMadison Ponder
Madison Ponder
KBKim A. Boggess
Kim A. Boggess
JEJessie K. Edwards
Jessie K. Edwards
MFMichele Jonsson Funk
Michele Jonsson Funk
MWMollie E Wood
Mollie E Wood
Background Limited data exist on the comparative effectiveness and safety of first-line medications to treat chronic hypertension in pregnancy. We compared nifedipine versus labetalol initiation before 23 weeks’ gestation for risk of pregnancy loss (miscarriage or stillbirth) and preterm birth (<37 weeks). Methods We identified pregnancies in Merative’s MarketScan commercial claims data with estimated last menstrual periods between July 1, 2016 and February 1, 2022. We included those with a new nifedipine or labetalol fill before 23 weeks’ gestation. We estimated risks, risk differences (RDs) per 100 pregnancies, and risk ratios (RRs) among nifedipine versus labetalol initiators using a weighted Aalen-Johansen estimator to account for confounding and informative censoring. We also conducted a post hoc analysis to estimate the comparative effect of nifedipine versus labetalol on risk of preeclampsia. Results We identified 987 nifedipine and 4,570 labetalol initiators during the study period. The weighted risk of pregnancy loss was 7.0% among nifedipine and 6.0% among labetalol initiators (RD=1.1 [-0.7, 2.8]; RR=1.18 [0.87, 1.59]). Weighted risks of preterm birth were 29.4% versus 22.2%, respectively (RD=7.2 [3.9, 10.5], RR=1.32 [1.13, 1.55]). In post hoc analyses, the weighted risks of preeclampsia were 38.6% versus 33.9%, respectively (RD=4.7 [0.7, 8.7], RR=1.14 [1.01, 1.28]). Findings were consistent across various sensitivity analyses. Conclusions Compared to labetalol initiators, nifedipine initiators experienced an increased risk of preterm birth but not pregnancy loss. The elevated risk of preterm birth may be explained by an increased risk of preeclampsia among nifedipine initiators, resulting in medically indicated preterm birth. What is new? Initiating nifedipine, compared to labetalol, before 23 weeks’ gestation as a first-line antihypertensive was associated with a 7.2 percentage point increased risk of preterm live birth (95% CI: 3.9, 10.5) and 4.7 percentage point increased risk of preeclampsia (95% CI: 0.7, 8.7). Nifedipine and labetalol were associated with a similar risk of pregnancy loss (risk difference: 1.1 per 100 pregnancies [95% CI: -0.7, 2.8]). These findings were robust across multiple sensitivity analyses. What are the clinical implications? Initiating labetalol, compared to nifedipine, prior to 23 weeks’ gestation for treatment of chronic hypertension in pregnancy may lead to lower risk of preeclampsia and preterm live birth in real-world settings. While high-quality data from clinical trials clearly support antihypertensive therapy for chronic hypertension in pregnancy, our findings illustrate that the first-line medications may have different comparative safety and effectiveness profiles. These data are important for informing shared decision-making between providers and patients managing chronic hypertension in pregnancy.